Multi-omics combined test performance effectiveness on opportunistic screening of high-risk liver cancer population
10.3760/cma.j.cn501113-20231125-00235
- VernacularTitle:多组学联合检测可对肝癌高危人群进行有效机会性筛查
- Author:
Chan XIE
1
;
Bingliang LIN
;
Hong DENG
;
Xiaohong ZHANG
;
Qiyi ZHAO
;
Zhiliang GAO
Author Information
1. 中山大学附属第三医院感染性疾病科 中山大学附属第三医院肝脏病医院,广州 510630
- Keywords:
Hepatocellular carcinoma;
Gene mutation;
Screening;
Tumor biomarker;
DNA methylation;
Early diagnosis
- From:
Chinese Journal of Hepatology
2024;32(2):140-147
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To validate the performance of a multi-omics combined test for early screening of high-risk liver cancer populations.Methods:173 high-risk patients with liver cancer were prospectively screened in a real-world setting, and 164 cases were finally enrolled. B-ultrasound, alpha-fetoprotein (AFP), and HCC screens were conducted in all patients. A multi-omics early screening test was performed for liver cancer in combination with multi-gene methylation, TP53/TERT/CTNNB1 mutations, AFP, and abnormal prothrombin (PIVKA-II). Differences in rates were compared using the chi-square test, adjusted chi-square test, or Fisher's exact probability method for count data. A non-parametric rank test (Mann-Whitney) was used to compare the differences between the two groups of data.Results:The HCCscreen detection had a sensitivity of 100% for liver cancer screening, 93.8% for liver cancer and precancerous diseases, 34.1% for positive predictive value, 99.2% for negative predictive value, and 0.89 for an area under the curve (AUC). Parallel detection of AFP, AFP+B-ultrasound, and methylation+mutation had a sensitivity/specificity and AUC of 31.3%/88.5% (AUC=0.78), 56.3%/88.2% (AUC=0.86), and 81.3%/82.4 % (AUC=0.84). At the same time, the disease severity range was significantly correlated with the methylation+mutation score, HCCscreen score, or positive detection rate (PDR). There was no significant correlation between AFP serum levels and methylation+mutation or HCCscreen scores, while there was a significant linear correlation between methylation+mutation scores and HCCscreen scores ( r ?=?0.73, P ?0.001). Conclusion:In real-world settings, HCCscreen shows high sensitivity for screening opportunistic, high-risk liver cancer populations. Furthermore, it may efficaciously detect liver cancer and precancerous diseases, with superior performance to AFP and AFP+ultrasound. Hence, HCCscreen has the potential to become an effective screening tool that is superior to existing screening methods for high-risk liver cancer populations.